Meet the Microbiome and Cancer Working Group

What can we do differently today to improve outcomes for cancer patients? 

One clear, evidence-based takeaway from today’s keynote at the Society for Immunotherapy of Cancer (SITC): clinicians should be judicious when prescribing antibiotics before or during immunotherapy. Multiple studies have shown that antibiotic use in these settings is associated with significantly shorter overall survival.

In her keynote address, Dr. Jen Wargo of MD Anderson Cancer Center also announced the launch of the Microbiome and Cancer Working Group — a new international initiative to deliver clear, evidence-based recommendations on how the microbiome can improve outcomes for every cancer patient.

Co-chaired by Dr. Arielle Elkrief of CHUM and Dr. Wargo, this global, multi-disciplinary team will bring together leading experts across oncology, immunology, microbiology, and public health to:

• Synthesize current scientific understanding of the microbiome and cancer
• Identify key research gaps
• Establish standards for evidence generation
• Define a clear path for integrating microbiome science into clinical care

Seerave is proud to sponsor this landmark initiative and to help connect the brightest minds working at the intersection of cancer and the microbiome. We believe that microbiome science has the power to transform cancer outcomes — not in decades, but starting today.

Further Reading: Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship